Skip to main content
SpringerLink
Log in

First annual report of the Austrian CML registry

Erster Jahresbericht des österreichischen CML-Registers

  • Original article
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Unter der Schirmherrschaft der österreichischen Gesellschaft für Hämatologie und Onkologie (ÖGHO) wurde das österreichische CML-Register gegründet, um österreichweit Krankheitsverläufe, Behandlungen, Nebenwirkungen und Therapieansprechen insbesondere auch der nicht in klinischen Studien erfassten Patienten zu dokumentieren und so ein besseres Bild der real-life Situation zu erlauben. Dieser Bericht fasst die Register-Daten mit Stichtag des 20.3.2009 zusammen. Bis zu diesem Stichtag sind insgesamt 179 Patienten mit 1012 Follow-ups und einer medianen Beobachtungszeit von 20 Monaten im Register erfasst. Dabei verteilen sich die Patienten wie folgt auf die verschiedenen Krankheitsphasen: 151 Patienten in chronischer und 4 in akzelerierter Phase. Die Registerpatienten wurden großteils (n = 137) mit Tyrosinkinaseinhibitoren (TKI) behandelt, daneben wurden auch Chemotherapeutika und Stammzelltransplantationen eingesetzt. 14 Patienten wurden sequentiell mit TKI der ersten und zweiten Generation behandelt und 15 Patienten erhielten niemals einen TKI. Die kumulativen Inzidenzraten für ein komplettes hämatologisches Ansprechen nach 12 und 24 Monaten betrugen 91.6 % und 94.4 %. Zu denselben Zeitpunkten wurde eine kumulative Inzidenz einer kompletten zytogenetischen Remission mit 64 % und 80 % ermittelt. Das Gesamtüberleben zu 60 Monaten betrug 90 % während das progressionsfreie Überleben (orientiert an den ELN-failure Kriterien) nach 60 Monaten bei 58 % lag.

Summary

The Austrian chronic myeloid leukemia (CML) registry monitors individual disease courses, treatments applied, clinical outcome, and side effects of CML patients on a nationwide basis to provide data on the "real-life" situation and to complement the information and interpretation gained from the selected patient population observed in clinical trials. This report summarizes the Austrian CML registry data as of March 2009. A total of 179 patients have been registered with a median number of 1012 follow-up visits and median observation duration of 20 months. At diagnosis most patients (n = 163) were in chronic phase (early, late, and secondary), whereas only 4 were in advanced phase. A total of 137 patients were treated with tyrosine kinase inhibitors (TKIs), of which 14 received first and second generation TKIs sequentially. Other treatment modalities included chemotherapy or interferon and stem cell transplantation (SCT). Cumulative incidence rates for complete hematological responses (CHR) were 91.6% and 94.4% at 12 and 24 months, respectively, compared to cumulative incidence rates of complete cytogenetical response rates of 64% and 80% at these timepoints. A total of 5 patients progressed from chronic phase to accelerated (n = 3) and blastic phase (n = 2) while receiving imatinib standard dose. Estimated overall survival (OS) rate at 60 months was 90% and progression free survival (PFS) according to European Leukemia Net (ELN) failure definition was 58%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290–3

    Article  CAS  PubMed  Google Scholar 

  • Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233(4760):212–4

    Article  CAS  PubMed  Google Scholar 

  • Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 2007;204(3):461–5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561–6

    Article  CAS  PubMed  Google Scholar 

  • Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038–42

    Article  CAS  PubMed  Google Scholar 

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031–7

    Article  CAS  PubMed  Google Scholar 

  • Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408–17

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108(6):1809–20

    Article  CAS  PubMed  Google Scholar 

  • Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, et al. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr 2008;120(21–22):697–709

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108(6):1809–20

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemiaNet. J Clin Oncol 2009;27(35):6041–51

    Article  CAS  PubMed  Google Scholar 

  • Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22(10):1963–6

    Article  CAS  PubMed  Google Scholar 

  • O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994–1004

    Article  PubMed  Google Scholar 

  • de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358–63

    Article  PubMed  Google Scholar 

  • Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540–6

    Article  CAS  PubMed  Google Scholar 

  • Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22(6):1200–6

    Article  CAS  PubMed  Google Scholar 

  • Sokal JE. Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Hematol 1987;1(4):907–29

    Article  CAS  Google Scholar 

  • Usman M, Syed NN, Kakepoto GN, Adil SN, Khurshid M. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. J Assoc Physicians India 2007;55:103–7

    CAS  PubMed  Google Scholar 

  • Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408–17

    Article  CAS  PubMed  Google Scholar 

  • Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054–61

    Article  CAS  PubMed  Google Scholar 

  • O'Brien S, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract #186

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, Haematology & Oncology, Innsbruck Medical University, Innsbruck, Austria

    Stefan Schmidt, Dominik Wolf & Günther Gastl

  2. Klinikum Wels – Grieskirchen, Wels, Austria

    Josef Thaler & Sonja Burgstaller

  3. Division of Hematology, Medical University of Graz, Graz, Austria

    Wolfgang Linkesch

  4. Krankenhaus der barmherzigen Schwestern, Linz, Austria

    Andreas Petzer

  5. Allgemeines Krankenhaus der Stadt Linz, Linz, Austria

    Michael Fridrik

  6. Landeskrankenhaus Feldkirch, Feldkirch, Austria

    Alois Lang

  7. Klinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseologie, Medizinische Universität Wien, Wien, Austria

    Hermine Agis & Peter Valent

  8. aö. Krankenhaus der Elisabethinen, Linz, Austria

    Otto Krieger

  9. aö. Bezirkskrankenhaus Lienz, Lienz, Austria

    Alois Walder

  10. Krankenhaus der barmherzigen Brüder, Eisenstadt, Austria

    Markus Korger

  11. Hanusch-Krankenhaus, Wien, Austria

    Ernst Schlögl

  12. Krankenhaus Wien-Hietzing, Wien, Austria

    Tamer Sliwa

  13. St. Vinzenz-Krankenhaus, Zams, Austria

    Ernst Wöll

  14. Krankenhaus Meran, Merano, Italy

    Manfred Mitterer

  15. Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria

    Wolfgang Eisterer

  16. Landeskrankenhaus St. Pölten, St. Pölten, Austria

    Michael Pober

Authors
  1. Stefan Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominik Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Josef Thaler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sonja Burgstaller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Linkesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas Petzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael Fridrik
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alois Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hermine Agis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Otto Krieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alois Walder
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Markus Korger
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ernst Schlögl
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tamer Sliwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Ernst Wöll
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Manfred Mitterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Wolfgang Eisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Michael Pober
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Günther Gastl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Schmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, S., Wolf, D., Thaler, J. et al. First annual report of the Austrian CML registry. Wien Klin Wochenschr 122, 558–566 (2010). https://doi.org/10.1007/s00508-010-1450-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-010-1450-x

Keywords

Search

Navigation